Retirement Systems of Alabama Decreases Stock Holdings in Hologic, Inc. $HOLX

Retirement Systems of Alabama lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 47.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 364,233 shares of the medical equipment provider’s stock after selling 332,855 shares during the quarter. Retirement Systems of Alabama owned 0.16% of Hologic worth $27,132,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in HOLX. Mn Services Vermogensbeheer B.V. lifted its holdings in shares of Hologic by 1.3% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 85,946 shares of the medical equipment provider’s stock valued at $6,402,000 after buying an additional 1,086 shares during the period. CIBRA Capital Ltd bought a new stake in shares of Hologic in the fourth quarter worth $4,681,000. Syquant Capital Sas bought a new stake in shares of Hologic in the fourth quarter worth $9,408,000. Czech National Bank increased its position in Hologic by 3.9% during the fourth quarter. Czech National Bank now owns 58,687 shares of the medical equipment provider’s stock valued at $4,372,000 after acquiring an additional 2,197 shares during the last quarter. Finally, Canvas Wealth Advisors LLC increased its position in Hologic by 11.8% during the fourth quarter. Canvas Wealth Advisors LLC now owns 4,125 shares of the medical equipment provider’s stock valued at $307,000 after acquiring an additional 437 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Argus cut Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price target for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Two analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Trading Up 0.1%

NASDAQ:HOLX opened at $75.59 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The firm has a market capitalization of $16.87 billion, a price-to-earnings ratio of 31.50, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.78. The business has a fifty day moving average price of $75.25 and a 200-day moving average price of $73.49.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm posted $0.87 earnings per share. Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.